Chemistry:Aleniglipron
From HandWiki
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics.[1] It is delivered orally and is in a Phase II trial as of 2023.[2][3][4] In June 2024, Structure Therapeutics reported positive topline data from a Phase 2a obesity study in which GSBR-1290 demonstrated clinically meaningful and statistically significant placebo-adjusted mean weight loss and generally favorable safety and tolerability results.[5]
References
- ↑ Mao, Ting; Meng, Qinghua; Zhang, Haizhen; Zhang, Jinqiang J.; Shi, Songting; Guan, Zhibo; Jiang, Xinglong; Zhang, Fang et al. (20 June 2023). "760-P: Discovery of GSBR-1290, a Highly Potent, Orally Available, Novel Small Molecule GLP-1 Receptor Agonist". Diabetes 72 (Supplement_1). doi:10.2337/db23-760-P.
- ↑ "Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity". 25 May 2023. https://www.biospace.com/article/releases/structure-therapeutics-initiates-phase-2a-study-of-oral-glp-1-agonist-gsbr-1290-for-the-treatment-of-type-2-diabetes-and-obesity/.
- ↑ "Structure announces positive results from oral GLP-1 receptor agonist gsbr-1290" (in en). 2 October 2023. https://www.bariatricnews.net/post/structure-announces-positive-results-from-oral-glp-1-receptor-agonist-gsbr-1290.
- ↑ Satija, Bhanvi (29 September 2023). "Structure Therapeutics surges as early data from obesity pill tops expectations" (in en). Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/structure-therapeutics-surges-promising-early-stage-obesity-drug-data-2023-09-29/.
- ↑ "Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290" (in en-US). 2024-06-03. https://www.biospace.com/structure-therapeutics-reports-positive-topline-data-from-its-phase-2a-obesity-study-and-capsule-to-tablet-pk-study-for-its-oral-non-peptide-small-molecule-glp-1-receptor-agonist-gsbr-1290.
 |  |
